Orchestra BioMed (OBIO) insider withholds 32,438 RSU shares for tax

Rhea-AI Filing Summary

Orchestra BioMed Holdings director and officer David P. Hochman reported a tax-related share disposition tied to restricted stock units. On the reported date, 32,438 shares of Common Stock at $4.57 per share were withheld by the company to satisfy RSU tax obligations, and no shares were sold in the market.

After this withholding, Hochman directly owns 1,054,029 shares of Common Stock. He also reports additional indirect holdings through several trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions in other family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	03/25/2026		F(1)		32,438	D	$4.57	1,054,029	D
Common Stock								439,482	I	By the DPH 2008 Trust
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did David P. Hochman report in his Form 4 for Orchestra BioMed (OBIO)?

David P. Hochman reported that Orchestra BioMed withheld 32,438 shares of Common Stock to cover tax obligations from vesting RSUs. These shares were not sold in the open market, but retained by the issuer specifically to satisfy his associated tax liability.

Did the Orchestra BioMed (OBIO) insider sell shares in the open market?

No, the filing states that no shares were sold in the market. Instead, 32,438 shares of Common Stock were withheld by Orchestra BioMed to satisfy tax withholding obligations related to the vesting of restricted stock units held by David P. Hochman.

How many Orchestra BioMed (OBIO) shares does David P. Hochman hold after this Form 4 transaction?

Following the tax withholding event, David P. Hochman directly holds 1,054,029 shares of Common Stock. He also reports indirect ownership through multiple family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller amounts in several 2019 family trusts.

What is the nature of the tax-withholding transaction reported by the OBIO insider?

The transaction is coded as a tax-withholding disposition related to vesting RSUs. Orchestra BioMed withheld 32,438 shares at a price of $4.57 per share to pay Hochman’s tax obligation, rather than him selling shares on the open market to generate cash.

What indirect Orchestra BioMed (OBIO) holdings are reported for David P. Hochman?

The Form 4 shows indirect holdings through several trusts. These include 439,482 shares held by the DPH 2008 Trust and positions of 2,000 shares each in three 2019 trusts, plus 3,140 shares held by the NSH 2008 Family Trust, all reported as indirect ownership.